Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P82930
UPID:
RT34_HUMAN
Alternative names:
28S ribosomal protein S34, mitochondrial
Alternative UPACC:
P82930; Q9BVI7
Background:
Small ribosomal subunit protein mS34, also known as 28S ribosomal protein S34, mitochondrial, is pivotal in mitochondrial translation. It ensures the stability of the small ribosomal subunit and the 12S rRNA, crucial for mitoribosome assembly.
Therapeutic significance:
Its association with Combined oxidative phosphorylation deficiency 32, a disorder marked by mitochondrial respiratory chain complexes deficiency, underscores its therapeutic potential. Understanding mS34's role could lead to novel treatments for mitochondrial diseases.